Canaccord analyst William J. Plovanic published a report on PhotoMedex PHMD that reiterated its Neutral rating and raised the price target from $18.50 to $19.50.
Canaccord reported that, “We reiterate our BUY rating post the release of strong results relative to
our and consensus expectations. Revenue results outperformed preannounced
results and were paired with a very strong beat on EPS,
demonstrating operating leverage capabilities of the business model.
Additionally, growth initiatives including geographic expansion for
consumer products and increased DTC for psoriasis treatment positions
PhotoMedex for continued growth.”
Shares of PhotoMedex closed at $15.89 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in